NEW YORK — UK bioinformatics firm PrecisionLife said on Wednesday that it has partnered with Sano Genetics to study the long-term effects of COVID-19 with the goal of identifying biomarkers and new treatments for the condition.
Under the terms of the deal, the companies will use PrecisionLife's combinatorial analytics platform to analyze anonymized patient data collected by Sano from roughly 3,000 UK adults with long COVID. The aim of the partnership is to identify biomarkers associated with risk for long COVID, as well as discover novel therapeutic targets and drug repositioning candidates for the condition.
Financial and other terms were not disclosed.
"Understanding how our genetics influence our response to COVID-19 is key to better protecting vulnerable people and developing effective treatments," Sano Cofounder and CEO Patrick Short said in a statement. "PrecisionLife's analysis of Sano Genetics' data will enable this deep biological understanding."
In mid-2020, PrecisionLife — formerly RowAnalytics — shifted its focus from selling software tools to pharmaceutical companies for rare disease drug discovery to in silico target validation and COVID-19 drug repurposing.
Earlier this year, Cambridge, UK-based Sano raised $11 million in a Series A financing round.